非快转运腹膜溶质转运速率患者更适合递增式腹膜透析
本研究纳入974例初始行持续不卧床腹膜透析且保有残余肾功能的患者,按腹膜溶质转运速率分为快转运与非快转运组,比较递增式与全剂量腹膜透析的临床结局。倾向性评分匹配后,非快转运组递增式透析维持时间更长,死亡、无尿及心血管死亡风险更低,而快转运组无此获益。
要点
- 非快转运患者递增式腹膜透析维持时间中位21.0个月,长于快转运组的15.6个月。
- 非快转运患者递增式透析较全剂量透析死亡风险HR 0.25、无尿风险HR 0.53、心血管死亡风险HR 0.36。
- 快转运患者未观察到递增式腹膜透析的上述临床获益。
核心结论
- 非快转运患者维持递增式腹膜透析时间更长,临床获益优于快转运患者,可能更适合递增式腹膜透析。
研究设计与样本
- 单中心研究,纳入974例初始行持续不卧床腹膜透析且保有残余肾功能的患者,按腹膜溶质转运速率分快转运与非快转运组,再分递增式与全剂量透析组,采用倾向性评分匹配比较结局。
主要发现
- 非快转运组递增式透析维持时间中位21.0个月,快转运组为15.6个月,P=0.011。
- 匹配后非快转运组递增式透析较全剂量透析死亡风险HR 0.25,P=0.002。
- 匹配后非快转运组递增式透析较全剂量透析无尿风险HR 0.53,P=0.003。
- 匹配后非快转运组递增式透析较全剂量透析心血管死亡风险HR 0.36,P=0.047。
- 快转运组未观察到递增式透析的上述临床获益。
临床怎么用
- 对于腹膜溶质转运速率非快的持续不卧床腹膜透析患者,可优先考虑递增式腹膜透析以延长透析维持时间并降低死亡、无尿及心血管死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Previous studies have shown that incremental peritoneal dialysis (iPD) improves the prognosis of patients on PD with tolerable residual kidney function (RKF). The peritoneal solute transfer rate (PSTR) characterizes peritoneal ultrafiltration and solute transfer. However, the most appropriate recipients of iPD have not been identified. Therefore, we hypothesized that patients with different PSTRs would experience different clinical benefits of iPD therapy. METHODS: We studied patients with RKF who initiated continuous ambulatory peritoneal dialysis (CAPD) at our center. The enrolled patients were allocated to fast and nonfast PSTR groups, and then to iPD or full-dose PD. To mitigate the influence of confounding factors, propensity score matching was employed. The clinical outcomes associated with iPD and full-dose PD in the fast and nonfast PSTR groups were compared. RESULTS: A total of 974 patients on CAPD were enrolled. The median duration of maintenance using iPD for the nonfast PSTR group was longer than that for the fast PSTR group (21.0 vs. 15.6 months, P=0.011). Patients in nonfast PSTR group who underwent iPD had lower risks of mortality [hazard ratio (HR) 0.25, P=0.002], anuria (HR 0.53, P=0.003), and cardiovascular (CV) mortality (HR 0.36, P=0.047) than those who underwent full-dose PD after matching. However, these clinical benefits of iPD therapy were not present in the fast PSTR group. CONCLUSION: Patients who show nonfast PSTR maintain iPD longer and experience superior clinical benefits compared with those who undergo fast PSTR. Therefore, patients who experience nonfast PSTR may be more suitable for iPD therapy than those who experience fast PSTR.
引用
- Guo J, Xin Y, Zhou T, et al. Patients With Nonfast Peritoneal Transfer Rate are More Suitable for Incremental Peritoneal Dialysis. Kidney Int Rep. 2025. PMID: 41278317. doi:10.1016/j.ekir.2025.08.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。